MedCity News November 21, 2023
Marissa Plescia

The DEA proposed a rule back in March that would roll back some of the Covid-19 flexibilities for the virtual prescribing of controlled substances, but has since extended the flexibilities. Stephanie Strong, founder and CEO of Boulder Care, feels confident that the DEA will continue to be open to the prescribing of these medications via telemedicine.

When the Drug Enforcement Administration (DEA) released its proposed rule that would remove some of the Covid-19 telehealth flexibilities for the prescribing of controlled substances, it caused an uproar from telehealth companies and advocates. But the DEA has since pivoted on that stance, holding listening sessions related to those rules and extending the flexibilities through December 31, 2024.

The fact that the DEA...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Digital Health, Govt Agencies, Health System / Hospital, Patient / Consumer, Provider, Technology, Telehealth
Related Articles:
Health/Care at Super Bowl LIX, GLP-1s, Kaiser and Tufts on Food-As-Medicine, and the RFK, Jr. Factor: A Health Consumer Check-In
How NIH funding cuts will impact hospitals and universities
Across Healthcare System, Stakeholders Share Responsibility For High Costs
AI’s Future in Healthcare: Balancing Innovation, Regulation, and Practicality
Healthcare enters AI agent era

Share This Article